|
Details
|
Specifications
|
|---|---|
|
CAS Number
|
1650550-25-6
|
|
Molecular Formula
|
C20H25F6N7O4S
|
|
Molecular Weight
|
573.51 g/mol.
|
|
Synonyms
|
Enasidenib methanesulfonate
|
|
Chemical Name
|
2-methyl-1-((4-(6-(trifluoromethyl) pyridin-2-yl)-6-((2-(Trifluoro methyl) pyridin-4-yl) amino)-1,2,5,6-tetrahydro-1,3,5-triazin-2-yl) amino) propan-2-ol methane sulfonate
|
|
Therapeutic use
|
Acute myeloid leukemia (AML)
|
|
Status
|
Tech pack available
|
|
Background
|
Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2). Enasidenib was approved by U.S. Food and Drug Administration on August 1, 2017.
|
|
Grade
|
In-house
|
|
Polymorph
|
Form III
|
|
Storage Temperature
|
Controlled room temperature (20?C ? 25?C)
|
Please Note: We partner exclusively with pharmaceutical manufacturers, biotech companies, and international trading firms. Minimum order quantities apply*Â
Disclaimer:Â
The information provided on this webpage is based on the best available knowledge at the time of publication; however, accuracy and completeness are not guaranteed. Product specifications may change without notice. It is the responsibility of the purchaser or user to verify suitability and compliance. This product is intended for research use only and is not approved for human consumption.
Happy Customers
Projects Successfully Completed
Established
PhD Experts Driving R&D Excellence
Team Size
World-Class API Manufacturing Sites
Global Audits Successfully Completed
Comprehensive CDMO Service Offerings
Everything You Need to Know About Shilpa Pharma
Please Note: We partner exclusively with pharmaceutical manufacturers, biotech companies, and international trading firms. Minimum order quantities apply*
